Drug Shortage Report for SANDOZ IRBESARTAN HCT
| Report ID | 129102 |
| Drug Identification Number | 02337428 |
| Brand name | SANDOZ IRBESARTAN HCT |
| Common or Proper name | SANDOZ IRBESARTAN HCT |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | IRBESARTAN HYDROCHLOROTHIAZIDE |
| Strength(s) | 150MG 12.5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 500 FCT BO |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2020-11-27 |
| Estimated end date | |
| Actual end date | 2020-12-04 |
| Shortage status | Resolved |
| Updated date | 2020-12-09 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2020-12-09 | French | Compare |
| v4 | 2020-12-09 | English | Compare |
| v3 | 2020-11-28 | English | Compare |
| v2 | 2020-11-27 | French | Compare |
| v1 | 2020-11-27 | English | Compare |
Showing 1 to 5 of 5